24.9 C
New York
Tuesday, June 6, 2023

Is Cassava Sciences Inc. (NASDAQ: SAVA) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Cassava Sciences Inc. (SAVA) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.03, or 0.12%, to $25.25. The Cassava Sciences Inc. has recorded 8,855 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Stocks Info

SAVA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $25.22 and fluctuated between $25.73 as its day high and $24.16 as its day low. The current market capitalization of Cassava Sciences Inc. is $1.07B. A total of 0.64 million shares were traded on the day, compared to an average of 713.88K shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, SAVA has seen 8 BUY and 2 SELL insider trades, representing the acquisition of 112,344 and the disposition of 5,139 shares. Over the last 12 months, there were 17 BUYs and 6 SELLs from insiders. Insiders purchased 359,063 shares during that period but sold 141,571.

In the most recent transaction, Barry Richard bought 77,276 shares of SAVA for 25.76 per share on Mar 07. After the transaction, the Director now owns 275,000 company shares. In a previous transaction on Mar 06, Barry Richard bought 11,565 shares at 26.13 per share. SAVA shares that Director owns now total 197,724.

Among the insiders who bought shares, Barry Richard acquired of 36,159 shares on Aug 23 at a per-share price of $23.79. This resulted in the Director holding 186,159 shares of SAVA after the transaction. In another insider transaction, Kupiec James William bought 2,500 shares at $24.44 per share on Aug 23. Company shares held by the Chief Clinical Dev. Officer now total 2,500.


Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. SAVA’s most recent ex-dividend date was 12/13/2012 when it declared a $5.25 quarterly dividend that was paid in cash on 12/24/2012.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for SAVA in the last 3 months, the mean price target is $112.00 with high estimates of $124.00 and low estimates of $100.00. In terms of 52-week highs and lows, SAVA has a high of $51.59 and a low of $13.84.

As of this writing, SAVA has an earnings estimate of -$0.59 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$0.58 per share and a lower estimate of -$0.6. The company reported an EPS of -$0.47 in the last quarter, which was 16.10% higher than expectations of -$0.56.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. SAVA’s latest balance sheet shows that the firm has $233.44M in Cash & Short Term Investments as of fiscal 2021. There were $236.00k in debt and $12.53M in liabilities at the time. Its Book Value Per Share was $4.89, while its Total Shareholder’s Equity was $253.91M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SAVA is Buy with a score of 5.00.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles